Amodiaquine/sulfadoxine/pyrimethamine

From WikiProjectMed
Jump to navigation Jump to search
Amodiaquine/sulfadoxine/pyrimethamine
Combination of
Amodiaquine4-Aminoquinolone[1]
SulfadoxineSulphonamide[1]
PyrimethamineDiaminopyrimidine[1]
Names
Trade namesSpaq-co;[2] others
Clinical data
Main usesPrevent malaria[1]
Side effectsVomiting, abdominal pain, diarrhea, headache, allergic reactions, liver problems, Steven–Johnson syndrome[3]

Amodiaquine/sulfadoxine/pyrimethamine are three medications sold together to prevent malaria.[4][1] Specifically it is used to prevent falciparum malaria in children 3 months to 5 years old in sub-Saharan Africa.[3][1][2] It is taken by mouth.[4] It is given over three days once per month for up to 4 months.[3]

Common side effects include vomiting, abdominal pain, diarrhea, headache, and allergic reactions.[3] Liver problems and Steven–Johnson syndrome may occur.[3] It should not be taken with sulfamethoxazole.[3] Pyrimethamine/sulfadoxine use in early pregnancy may harm the baby; though maybe used in later pregnancy.[3] It contains amodiaquine tablets, which blocks haem detoxification; and pyrimethamine/sulfadoxine tablets, which blocks dihydropteroate synthase and plasmodial dihydrofolate reductase.[3][1]

The combination received World Health Organization prequalification in 2014.[5] It is on the World Health Organization's List of Essential Medicines.[6] Fifty courses of treatment costs about 16 USD as of 2023.[1]

Medical uses

Dosage

It comes in two different strengths of pills.[7]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "Amod 153mg+ SP 525mg disp tab/3+1/PAC-50". supply.unicef.org. Archived from the original on 26 March 2023. Retrieved 17 September 2023.
  2. ↑ 2.0 2.1 "Amodiaquine (as hydrochloride) 76.5 mg Dispersible Tablets + Pyrimethamine/Sulfadoxine 12.5 mg/250 mg Tablets" (PDF). WHO. Archived (PDF) from the original on 19 September 2023. Retrieved 17 September 2023.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 "WHO-PQ RECOMMENDED SUMMARY OF PRODUCT CHARACTERISTICS" (PDF). WHO. Archived (PDF) from the original on 19 September 2023. Retrieved 17 September 2023.
  4. ↑ 4.0 4.1 "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 4 June 2023. Retrieved 16 September 2023.
  5. ↑ "First sulfadoxine/pyrimethamine + amodiaquine prequalified". WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). 20 October 2014. Archived from the original on 19 September 2023. Retrieved 18 September 2023.
  6. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  7. ↑ "Macleods' Pyrimethamine/Sulfadoxine + Amodiaquine (hydrochloride) dispersible tablets prequalified". WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). 4 November 2022. Archived from the original on 19 September 2023. Retrieved 18 September 2023.
Retrieved from "https://mdwiki.org/w/index.php?title=Amodiaquine/sulfadoxine/pyrimethamine&oldid=1368682"